 |
Indication & Dosage |
| |
| |
| Parenteral |
| POSTOPERATIVE PAIN |
| Adult:
40 mg slow IM or IV inj, then 20 or 40 mg every 6-12 hr as required. Max dose: 80 mg/day. |
| |
| Parenteral |
| POSTOPERATIVE PAIN |
| Child:
<18 yr: Not recommended.
Elderly: <50 kg: 20 mg slow IM or IV injection, repeat to a max of 40 mg/day. |
|
| |
|
| Precautions |
Elderly, children ; history of GI ulceration, perforation or bleed; oedema; dehydration; hyperlipidaemia; DM; hypertension; liver or kidney disease; concurrent infection. May impair ability to drive or operate machinery. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Rash, ulcerations or any other signs of an allergic reaction; GI disturbances and bleeding; hypotension; hypertension; back pain; oedema; numbness; agitation or sleeping difficulties; anaemia; sore throat or difficulty breathing; pruritus; decreased urine output; jaundice, abnormal liver function; low platelet count; skin swelling, blistering or peeling; kidney failure; heart failure, heart attack, bradycardia, arrhythmia. |
| |
|
| Adverse Drug Reactions |
Anaphylaxis, Steven-Johnson syndrome, toxic epidermal necrolysis. |
| |
|
| Interactions |
Enhances effects of oral anticoagulants (azapropazone and phenylbutazone); increases plasma concentrations of lithium, methotrexate, and cardiac glycosides; increased risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus, or diuretics; reduces antihypertensive effects of some antihypertensives (ACE inhibitors, beta blockers, diuretics); occurrence of convulsions with quinolones; increases effects of phenytoin and sulfonylurea antidiabetics; increased risk of adverse effects with other NSAIDs (including aspirin) and misoprostol; risk of GI bleeding and ulceration increased with corticosteroids, SSRIs, the SNRI venlafaxine, the antiplatelets clopidogrel and ticlopidine, iloprost, erlotinib, sibutramine, alcohol, bisphosphonates, or pentoxifylline; increased risk of haematotoxicity with zidovudine; increased plasma concentrations with ritonavir; may alter the efficacy of mifepristone; metabolism may be decreased with CYP3A4 (e.g ketoconazole) and CYP2C9 inhibitors (e.g. fluconazole), or increased with enzyme inducers (e.g. carbamazepine, dexamethasone). |
| |
|
|
|
